Eagle Asset Management Inc. lowered its holdings in shares of FibroGen Inc (NASDAQ:FGEN) by 1.3% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 818,865 shares of the biopharmaceutical company’s stock after selling 10,573 shares during the period. Eagle Asset Management Inc. owned 1.00% of FibroGen worth $39,034,000 as of its most recent filing with the SEC.
Other institutional investors have also bought and sold shares of the company. Bank of Montreal Can increased its holdings in shares of FibroGen by 2,097.2% during the fourth quarter. Bank of Montreal Can now owns 3,186 shares of the biopharmaceutical company’s stock worth $151,000 after buying an additional 3,041 shares in the last quarter. Fortaleza Asset Management Inc. increased its holdings in FibroGen by 95.0% in the fourth quarter. Fortaleza Asset Management Inc. now owns 3,490 shares of the biopharmaceutical company’s stock valued at $165,000 after purchasing an additional 1,700 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in FibroGen by 41.9% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,883 shares of the biopharmaceutical company’s stock valued at $184,000 after acquiring an additional 1,147 shares during the last quarter. Oppenheimer Asset Management Inc. boosted its position in FibroGen by 112.6% during the third quarter. Oppenheimer Asset Management Inc. now owns 4,410 shares of the biopharmaceutical company’s stock valued at $237,000 after acquiring an additional 2,336 shares during the last quarter. Finally, Ameritas Investment Partners Inc. boosted its position in FibroGen by 15.4% during the second quarter. Ameritas Investment Partners Inc. now owns 5,218 shares of the biopharmaceutical company’s stock valued at $169,000 after acquiring an additional 696 shares during the last quarter. Institutional investors and hedge funds own 61.39% of the company’s stock.
A number of research firms have recently issued reports on FGEN. ValuEngine cut shares of FibroGen from a “hold” rating to a “sell” rating in a research report on Friday, December 1st. BidaskClub lowered shares of FibroGen from a “hold” rating to a “sell” rating in a report on Thursday, December 7th. Leerink Swann restated an “outperform” rating and issued a $88.00 target price (up previously from $80.00) on shares of FibroGen in a report on Wednesday, February 28th. TheStreet upgraded shares of FibroGen from a “d” rating to a “c-” rating in a research note on Tuesday, February 27th. Finally, Zacks Investment Research lowered shares of FibroGen from a “hold” rating to a “sell” rating in a research note on Monday, March 5th. Two research analysts have rated the stock with a sell rating, three have assigned a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus target price of $66.67.
In related news, insider K Peony Yu sold 10,000 shares of the business’s stock in a transaction dated Monday, January 29th. The shares were sold at an average price of $62.00, for a total transaction of $620,000.00. Following the sale, the insider now owns 152,086 shares of the company’s stock, valued at $9,429,332. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Thomas B. Neff sold 18,900 shares of the business’s stock in a transaction dated Thursday, December 14th. The stock was sold at an average price of $42.71, for a total transaction of $807,219.00. Following the sale, the chief executive officer now directly owns 3,060,887 shares in the company, valued at approximately $130,730,483.77. The disclosure for this sale can be found here. In the last quarter, insiders sold 442,237 shares of company stock worth $22,895,036. 13.60% of the stock is owned by corporate insiders.
FibroGen Inc (NASDAQ FGEN) traded down $0.65 during midday trading on Monday, hitting $54.80. 396,594 shares of the stock were exchanged, compared to its average volume of 688,853. The company has a market cap of $4,530.00, a P/E ratio of -31.14 and a beta of 1.76. FibroGen Inc has a 52 week low of $22.75 and a 52 week high of $63.00. The company has a debt-to-equity ratio of 0.17, a current ratio of 9.70 and a quick ratio of 9.70.
COPYRIGHT VIOLATION NOTICE: “Eagle Asset Management Inc. Has $39.03 Million Stake in FibroGen Inc (FGEN)” was originally posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this article on another website, it was stolen and republished in violation of U.S. and international copyright & trademark law. The legal version of this article can be viewed at https://ledgergazette.com/2018/03/13/eagle-asset-management-inc-sells-10573-shares-of-fibrogen-inc-fgen.html.
FibroGen Company Profile
FibroGen, Inc is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer.
Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.